Jerry L. Adams

TL;DR: Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl-imidazole compounds, suggesting that the CSBPs are critical for cytokine production.

TL;DR: A novel profile of activity strongly suggests that cytokine inhibitors could provide significant benefit in the therapy of chronic inflammatory disease.

TL;DR: A linking strategy to synergize the effect of two symmetry-related amidobenzimidazole-based compounds to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function is developed, representing a milestone in the rapidly growing field of immune-modifying cancer therapies.

TL;DR: Agents aimed at mechanisms — modulation of the immune response, trafficking to the tumour microenvironment and cellular infiltration — are poised to significantly extend the scope of immuno-oncology applications and enhance the opportunities for combination with tumour-targeted agents and biologic immunotherapies.

TL;DR: X-ray crystallographic analysis of p38-inhibitor complexes reinforces the observations made from site-directed mutagenesis studies, thereby providing a molecular basis for understanding the kinase selectivity of these inhibitors.